A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

Full Title	A Phase 2, Randomized, Open-label (With Blinded Plasminogen Activator and Placebo Control Groups) Study to Evaluate the Effects of Different Intra-thrombus Infusion Regimens of Plasmin (Human) Compared to Plasminogen Activator and Placebo In Patients With Acute Lower Extremity Native Artery or Bypass Graft Occlusion
Protocol Number	T05018-2004
clinicaltrials.gov	http://clinicaltrials.gov/show/NCT01222117
Principal Investigator(s)	John R Hoch, MD
Division	Vascular Surgery
Status	Recruiting
Description	The primary purpose of this Phase 2 study is to optimize Plasmin delivery by comparing 4 different delivery regimens in patients with acute peripheral arterial occlusion. The study will also compare Plasmin to placebo and to plasminogen activators. The study will further assess the safety and tolerability of Plasmin at the 150 mg dose.